AstraZeneca topped the first annual Pharmaceutical Invention Index, released by IDEA Pharma.
Ardelyx’s Phase III AMPLIFY study of tenapanor achieved the clinical trial’s primary endpoint, as well as all key secondary endpoints, in treating patients with chronic kidney disease (CKD).
The U.S. Food and Drug Administration granted fast track status for the development of AstraZeneca’s diabetes drug Farxiga to prevent heart and kidney failure in patients with chronic kidney disease.
The Trump administration plans to change the way it pays for kidney disease treatments to favor lower cost care at home and transplants over the current standard, dialysis clinics, top health officials said during a press briefing.
Stamford, Conn.-based Cara Therapeutics announced positive topline results from the company’s KALM-1 Phase III trial of Korsuva (CR845/difelikefalin) Injection in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus.
Janssen’s Invokana became the only medicine in nearly 20 years and the first diabetes medicine ever to demonstrate a reduction in progression to end-stage renal failure in T2D patients with CKD.
Proteon Therapeutics announced that the Waltham, Mass.-based company’s PATENCY-2 Phase III clinical trial of vonapanitase in chronic kidney disease failed to meet the study’s co-primary endpoints.
Novo Nordisk submitted the company’s oral semaglutide drug, a pill that management hopes will transform the diabetes market, for approval in the United States.
AstraZeneca released positive data from two clinical trials of roxadustat in anemia and of the company’s study of Lynparza in ovarian cancer.
China became the first country to approve a new anemia drug from AstraZeneca and FibroGen, well before decisions by regulators in the United States or Europe.